Why Spark Therapeutics Is Skyrocketing 120% Today [www.fool.com]
Why There Is No Sticker Shock in Biotech [www.wsj.com]
Are you a robot? [www.bloomberg.com]
Roche to buy gene therapy specialist Spark in $4.3 billion deal [www.cnbc.com]
$ARWR Now profitable (300M+ free cash flow) w/primary market high margin orphan drugs~Did I mentioning $JNJ $ARWR HBV+ gene-silencing drug deal worth up to $3.7 billion? ( $AMGN deals potential maxed in B's? +Pivotal PH2 A1AD plausibility.~Valuate that? https://t.co/oYwsslopcQ
— truthtracer (@truthtracer) February 25, 2019
Sticker shock in biotech? I think not. $XBI $ONCE https://t.co/nUqMloKSwn
— Charley Grant (@CGrantWSJ) February 25, 2019
So it looks like a done deal, Roche is buying Spark for $4.3 billion US dollars. I suspect the main reason for buying Spark is its #hemophilia gene therapy portfolio. https://t.co/xw4PWN3Uso #haemophilia
— Michael Makris (@ProfMakris) February 25, 2019